Treatment results and prognostic factors in primary thyroid lymphoma patients: a Rare Cancer Network study

dc.contributor.authorOnal, C.
dc.contributor.authorLi, Y. X.
dc.contributor.authorMiller, R. C.
dc.contributor.authorPoortmans, P.
dc.contributor.authorConstantinou, N.
dc.contributor.authorWeber, D. C.
dc.contributor.authorAtasoy, B. M.
dc.contributor.authorIgdem, S.
dc.contributor.authorOzsahin, M.
dc.contributor.authorOzyar, E.
dc.date.accessioned2023-02-21T12:41:27Z
dc.date.available2023-02-21T12:41:27Z
dc.date.issued2011-01-01
dc.description.abstractBackground: This study analyzed prognostic factors and treatment outcomes of primary thyroid lymphoma. Patients and Methods: Data were retrospectively collected for 87 patients (53 stage I and 34 stage II) with median age 65 years. Fifty-two patients were treated with single modality (31 with chemotherapy alone and 21 with radiotherapy alone) and 35 with combined modality treatment. Median follow-up was 51 months. Results: Sixty patients had aggressive lymphoma and 27 had indolent lymphoma. The 5- and 10-year overall survival (OS) rates were 74\% and 71\%, respectively, and the disease-free survival (DFS) rates were 68\% and 64\%. Univariate analysis revealed that age, tumor size, stage, lymph node involvement, B symptoms, and treatment modality were prognostic factors for OS, DFS, and local control (LC). Patients with thyroiditis had significantly better LC rates. In multivariate analysis, OS was influenced by age, B symptoms, lymph node involvement, and tumor size, whereas DFS and LC were influenced by B symptoms and tumor size. Compared with single modality treatment, patients treated with combined modality had better 5-year OS, DFS, and LC. Conclusions: Combined modality leads to an excellent prognosis for patients with aggressive lymphoma but does not improve OS and LC in patients with indolent lymphoma.
dc.description.issue1
dc.description.issueJAN
dc.description.pages156-164
dc.description.volume22
dc.identifier.doi10.1093/annonc/mdq310
dc.identifier.urihttps://hdl.handle.net/11443/2720
dc.identifier.urihttp://dx.doi.org/10.1093/annonc/mdq310
dc.identifier.wosWOS:000285414800023
dc.publisherOXFORD UNIV PRESS
dc.relation.ispartofANNALS OF ONCOLOGY
dc.subjectchemotherapy
dc.subjectcombined modality treatment
dc.subjectnon-Hodgkin's lymphoma
dc.subjectprognostic factors
dc.subjectradiotherapy
dc.subjectthyroid lymphoma
dc.titleTreatment results and prognostic factors in primary thyroid lymphoma patients: a Rare Cancer Network study
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Treatment results and prognostic factors in primary thyroid lymphoma patients a Rare CancerNetwork study.pdf
Size:
205.39 KB
Format:
Adobe Portable Document Format

Collections